COST-EFFECTIVENESS ANALYSIS OF ORAL SEMAGLUTIDE AS THE SECOND-LINE AND THIRD-LINE TREATMENT FOR TYPE 2 DIABETES PATIENT

被引：0
|
作者：
Tan, E. C. H. [1 ]
Yang, M. C. [2 ]
机构：
[1] China Med Univ, Dept Hlth Serv Adm, Taichung, Taiwan
[2] Natl Taiwan Univ, Taipei, Taiwan
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE15
引用
收藏
页码：S52 / S53
页数：2
相关论文
共 50 条
  • [31] Pembrolizumab as second-line therapy of hepatocellular carcinoma: A cost-effectiveness analysis
    Chan, S.
    Chiang, C.
    Lee, S.
    Wong, I.
    Choi, H.
    [J]. ANNALS OF ONCOLOGY, 2020, 31 : S174 - S174
  • [32] COST-EFFECTIVENESS OF CRIZOTINIB FOR SECOND AND THIRD-LINE TREATMENT OF NON-SMALL CELL LUNG CANCER IN ECUADOR
    Freire, V
    Cabezas, M.
    Salcedo, E.
    Albert, A.
    [J]. VALUE IN HEALTH, 2018, 21 : S30 - S31
  • [33] A RESPONSE TO: "COST-EFFECTIVENESS OF ORAL SEMAGLUTIDE ADDED TO CURRENT ANTIHYPERGLYCEMIC TREATMENT FOR TYPE 2 DIABETES"
    Kohli-Lynch, Ciaran N.
    Ruiz-Negron, Natalia
    Beal, Amy
    Bellows, Brandon K.
    [J]. JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2021, 27 (08): : 1140 - 1141
  • [34] After standard treatment, do the second-line and third-line treatments make sense?
    Sabbatini, R
    Maur, M
    Mucciarini, C
    Conte, PF
    [J]. TUMORI, 2003, : S33 - S34
  • [35] The cost-effectiveness of oral semaglutide versus empagliflozin in Type 2 diabetes in Denmark
    Ehlers, Lars H.
    Lamotte, Mark
    Ramos, Mafalda C.
    Sandgaard, Susanne
    Holmgaard, Pia
    Frary, Evan C.
    Ejskjaer, Niels
    [J]. JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2021, 11 (01) : 29 - 37
  • [36] Cost-effectiveness of nivolumab monotherapy in the third-line treatment of small cell lung cancer
    Smare, Caitlin
    Dave, Kiran
    Juarez-Garcia, Ariadna
    Abraham, Pranav
    Penrod, John R.
    Camidge, D. Ross
    Yuan, Yong
    [J]. JOURNAL OF MEDICAL ECONOMICS, 2021, 24 (01) : 1124 - 1133
  • [37] COST-EFFECTIVENESS ANALYSIS OF THE THIRD-LINE TREATMENT OF REGORAFENIB FOR METASTATIC OR UNRESECTABLE GASTROINTESTINAL STROMAL TUMORS IN CHINA
    Wang, Y.
    Rui, M.
    Cao, Y. D.
    Fei, Z.
    Ma, A. X.
    Li, H. C.
    [J]. VALUE IN HEALTH, 2021, 24 : S28 - S28
  • [38] COST-EFFECTIVENESS OF RITUXIMAB AS SECOND-LINE BIOLOGICAL TREATMENT COMPARED TO REGISTRY DATA
    Kobelt, G.
    Lindgren, P.
    [J]. VALUE IN HEALTH, 2008, 11 (06) : A548 - A548
  • [39] Cost-Effectiveness of Saxagliptin Compared With Glibenclamide as a Second-Line Therapy Added to Metformin for Type 2 Diabetes Mellitus in Ethiopia
    Bekele, Mengistu
    Norheim, Ole Frithjof
    Hailu, Alemayehu
    [J]. MDM POLICY & PRACTICE, 2021, 6 (01)
  • [40] Cost-Effectiveness of Sorafenib for Second-Line Treatment of Advanced Renal Cell Carcinoma
    Hoyle, Martin
    Green, Colin
    Thompson-Coon, Jo
    Liu, Zulian
    Welch, Karen
    Moxham, Tiffany
    Stein, Ken
    [J]. VALUE IN HEALTH, 2010, 13 (01) : 55 - 60
12345